Recruiting
Phase 1
Phase 2

BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours

Sponsor:

Bold Therapeutics, Inc.

Code:

NCT04421820

Conditions

Colorectal Cancer

Pancreatic Cancer

Gastric Cancers

Cholangiocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)

BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information